Table 14.
Anti‐HIV activity of 37 and 38 against selected clinical isolates highly resistant to multiple protease inhibitors.
|
Virus[a] |
IC50 [nm] values |
|||||
|---|---|---|---|---|---|---|
|
IDV |
RTV |
APV |
DRV |
37 |
38 |
|
|
ERS104pre (wild‐type) |
26 |
34 |
33 |
3.5 |
20 |
6 |
|
MDR/TM |
>1000 (>38) |
>1000 (>29) |
290 (9) |
4 (1) |
220 (11) |
64 (10) |
|
MDR/MM |
>1000 (>38) |
>1000 (>29) |
300 (9) |
17 (5) |
250 (13) |
110 (5) |
|
MDR/JSL |
>1000 (>38) |
>1000 (>29) |
430 (13) |
26 (7) |
500 (25) |
330 (55) |
|
MDR/B |
>1000 (>38) |
>1000 (>29) |
320 (10) |
26 (7) |
340 (17) |
230 (38) |
|
MDR/C |
>1000 (>38) |
>1000 (>29) |
230 (7) |
7 (2) |
210 (11) |
160 (27) |
|
MDR/G |
290 (11) |
>1000 (>29) |
340 (10) |
7 (2) |
360 (18) |
300 (50) |
|
MDR/A |
>1000 (>38) |
>1000 (>29) |
100 (3) |
3 (1) |
20 (1) |
13 (2) |
[a] Amino acid substitutions identified in the protease‐encoding region compared to the consensus type B sequence cited from the Los Alamos database, see reference 133.